Ernexa Therapeutics Inc.
NASDAQERNA cost to borrow surges to 873%, up 126% over the past week as borrowing demand intensifies following a 59% single-day earnings move.
Ernexa Therapeutics walks into its May 14 earnings event with one of the most charged short-selling setups in the micro-cap biotech universe. The borrow market tells the clearest story. Cost to borrow has exploded to…
ERNA — Ernexa Therapeutics — is printing its highest-ever cost to borrow. At 893.8% annualized, the figure has more than doubled in a single session and tripled over the past week. Earnings hit yesterday. Another…
Snapshot as of 22 Jun 2026
Ernexa Therapeutics heads into its May 7 earnings report with two catalysts colliding at once — a 1-for-25 reverse stock split that went live May 4 and fresh preclinical data that briefly triggered a circuit breaker…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ERNA — free to start on ORTEX.
Sign up for free →Open ERNA on ORTEX